Protein Identified That Boosts Brain Tumor Resistance to Chemotherapy
|
By LabMedica International staff writers Posted on 26 Jan 2016 |

Image: Space-filling model of the anticancer drug temozolomide (Photo courtesy of Wikimedia Commons).
Cancer researchers have linked development of resistance to the anticancer drug temozolomide by glioblastoma multiforme (GBM) brain cancer cells to the activity of the RhoG-specific guanine nucleotide exchange factor protein SGEF.
GBM is the highest grade and most common form of primary adult brain tumors. Despite surgical removal followed by concomitant radiation and chemotherapy with the alkylating agent temozolomide (TMZ), GBM tumors develop treatment resistance and ultimately recur. Impaired response to treatment occurs rapidly, conferring a median survival of just fifteen months. Thus, researchers are seeking to identify the genetic and signaling mechanisms that promote tumor resistance in order to develop targeted therapies to combat this refractory disease.
The therapeutic benefit of TMZ depends on its ability to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions of guanine residues. This methylation damages the DNA and triggers the death of tumor cells. However, some tumor cells are able to repair this type of DNA damage, and therefore diminish the therapeutic efficacy of TMZ, by expressing the protein O6-alkylguanine DNA alkyltransferase (AGT) encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. In some tumors, epigenetic silencing of the MGMT gene prevents the synthesis of this enzyme, and as a consequence such tumors are more sensitive to killing by TMZ. Conversely, the presence of AGT protein in brain tumors predicts poor response to TMZ and these patients receive little benefit from chemotherapy with this drug.
Previous studies have shown that SGEF (Src homology 3 domain-containing guanine nucleotide exchange factor) was overexpressed in GBM tumors and played a role in promoting TWEAK-Fn14–mediated glioma invasion. TWEAK is a multifunctional cytokine that controls many cellular activities including proliferation, migration, differentiation, apoptosis, angiogenesis, and inflammation. TWEAK acts by binding to Fn14, a highly inducible cell-surface receptor that is linked to several intracellular signaling pathways, including the nuclear factor-kappaB (NF-kappaB) pathway. The TWEAK–Fn14 axis normally regulates various physiological processes; in particular it seems to play an important, beneficial role in tissue repair following acute injury. Furthermore, recent studies have indicated that TWEAK–Fn14 axis signaling may contribute to cancer, chronic autoimmune diseases, and acute ischemic stroke.
Investigators at The Translational Genomics Research Institute (Phoenix, AZ, USA) reported in the January 13, 2016, online edition of the journal Molecular Cancer Research that SGEF expression was upregulated by TWEAK-Fn14 signaling via NF-kappaB activity while shRNA (short hairpin RNA)-mediated reduction of SGEF expression sensitized glioma cells to temozolomide-induced apoptosis and suppressed colony formation following temozolomide treatment.
Nuclear SGEF was activated following temozolomide exposure and formed complexes with the DNA damage repair protein BRCA1 (breast cancer 1), which enabled tumor cells to rapidly repair the damaged DNA that otherwise would lead to cell death. In contrast, BRCA1 phosphorylation in response to temozolomide treatment was hindered by inhibition of SGEF.
"We need to identify the genetic and cellular-pathway signaling mechanisms that make brain tumors resistant to treatment," said senior author Dr. Nhan Tran, head of the central nervous system tumor research laboratory at The Translational Genomics Research Institute. "And the role of SGEF in promoting chemotherapeutic resistance highlights this previously unappreciated protein. Importantly, this also suggests that SGEF could be a new candidate for development of targeted therapeutics."
Related Links:
The Translational Genomics Research Institute
GBM is the highest grade and most common form of primary adult brain tumors. Despite surgical removal followed by concomitant radiation and chemotherapy with the alkylating agent temozolomide (TMZ), GBM tumors develop treatment resistance and ultimately recur. Impaired response to treatment occurs rapidly, conferring a median survival of just fifteen months. Thus, researchers are seeking to identify the genetic and signaling mechanisms that promote tumor resistance in order to develop targeted therapies to combat this refractory disease.
The therapeutic benefit of TMZ depends on its ability to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions of guanine residues. This methylation damages the DNA and triggers the death of tumor cells. However, some tumor cells are able to repair this type of DNA damage, and therefore diminish the therapeutic efficacy of TMZ, by expressing the protein O6-alkylguanine DNA alkyltransferase (AGT) encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. In some tumors, epigenetic silencing of the MGMT gene prevents the synthesis of this enzyme, and as a consequence such tumors are more sensitive to killing by TMZ. Conversely, the presence of AGT protein in brain tumors predicts poor response to TMZ and these patients receive little benefit from chemotherapy with this drug.
Previous studies have shown that SGEF (Src homology 3 domain-containing guanine nucleotide exchange factor) was overexpressed in GBM tumors and played a role in promoting TWEAK-Fn14–mediated glioma invasion. TWEAK is a multifunctional cytokine that controls many cellular activities including proliferation, migration, differentiation, apoptosis, angiogenesis, and inflammation. TWEAK acts by binding to Fn14, a highly inducible cell-surface receptor that is linked to several intracellular signaling pathways, including the nuclear factor-kappaB (NF-kappaB) pathway. The TWEAK–Fn14 axis normally regulates various physiological processes; in particular it seems to play an important, beneficial role in tissue repair following acute injury. Furthermore, recent studies have indicated that TWEAK–Fn14 axis signaling may contribute to cancer, chronic autoimmune diseases, and acute ischemic stroke.
Investigators at The Translational Genomics Research Institute (Phoenix, AZ, USA) reported in the January 13, 2016, online edition of the journal Molecular Cancer Research that SGEF expression was upregulated by TWEAK-Fn14 signaling via NF-kappaB activity while shRNA (short hairpin RNA)-mediated reduction of SGEF expression sensitized glioma cells to temozolomide-induced apoptosis and suppressed colony formation following temozolomide treatment.
Nuclear SGEF was activated following temozolomide exposure and formed complexes with the DNA damage repair protein BRCA1 (breast cancer 1), which enabled tumor cells to rapidly repair the damaged DNA that otherwise would lead to cell death. In contrast, BRCA1 phosphorylation in response to temozolomide treatment was hindered by inhibition of SGEF.
"We need to identify the genetic and cellular-pathway signaling mechanisms that make brain tumors resistant to treatment," said senior author Dr. Nhan Tran, head of the central nervous system tumor research laboratory at The Translational Genomics Research Institute. "And the role of SGEF in promoting chemotherapeutic resistance highlights this previously unappreciated protein. Importantly, this also suggests that SGEF could be a new candidate for development of targeted therapeutics."
Related Links:
The Translational Genomics Research Institute
Latest BioResearch News
- BRCA2 Variant Analysis Offers Insights Into Breast Cancer Risk and Treatment
- Statistical Model Helps Track T Cell Behavior During Cancer Immunotherapy
- Blood NAD Levels May Offer Clues to Cardiovascular Health
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







